Moderna shares fall 2.68% after Q2 2026 cash balance drops to $6.9 billion following $950 million settlement payment
Moderna's Q2'26 revenue beat expectations and 2026 sales guidance was reaffirmed, but investor focus shifted to liquidity and pipeline risk. Cash fell to $6.9B from $7.5B, largely due to a $950M litigation settlement payment, highlighting sizable cash outflows. Additionally, the norovirus vaccine missed interim success criteria, offsetting optimism ahead of the August 5 PDUFA decision for its flu candidate.
AI Insight · NCSKMRNA2USD/USDTAI Insight
▼ Bearish
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Moderna reported second-quarter 2026 revenue of $145 million, topping expectations. However, cash and cash equivalents fell to $6.9 billion from $7.5 billion at the end of March, mainly after a $950 million litigation settlement payment in July. R&D spending declined 7% year over year as several late-stage programs wound down. The company reaffirmed its full-year 2026 sales guidance and said it expects roughly 50% of revenue to come from international markets, but the stock fell Friday as investors focused on liquidity pressure from the large cash outflow.